Core Viewpoint - Jingtai Technology (02228) has seen a stock price increase of nearly 5%, currently trading at 13.4 HKD, with a transaction volume of 596 million HKD, following the presentation of its incubated company, Laiman Bio, at the 44th J.P. Morgan Healthcare Conference, showcasing the latest results of its ultra-low dose CAR-T therapy [1] Group 1 - Laiman Bio, supported by Jingtai Technology, has developed multiple research pipelines based on its AI + immune metabolism reprogramming platform [1] - The enhanced CD19 CAR-T therapy has achieved a complete response (100% CR) in systemic lupus erythematosus patients using a dose as low as one-thousandth (1‰) of conventional CAR-T treatment, indicating a new possibility for "outpatient" CAR-T therapy [1] - This therapy has also led to complete responses in several patients with refractory leukemia/lymphoma, with multiple clinical trials for solid tumors either ongoing or about to start [1] Group 2 - Jingtai Technology and Laiman Bio have collaborated to develop the META 10-AI platform, which optimizes core metabolic enhancers used in the enhanced CAR-T therapy, significantly increasing their affinity by hundreds of times [2] - The results of this optimization have been applied for a patent in China and are being utilized in the development of metabolic-enhanced CAR-T pipelines targeting solid tumors, greatly improving the anti-exhaustion capability of CAR-T cells in the solid tumor immune microenvironment [2]
港股异动 | 晶泰科技(02228)盘中涨近5% 赋能莱芒生物取得细胞疗法重大成果 多个实体瘤领域IIT临床将启动